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 Introduction
Hyponatraemia, defined as a decrease in serum sodium con-
centration < 136 mEq/l, represents the most common electro-
lyte disorder in clinical practice. In particular, mild hypo-
natraemia (serum Na+ 130–135 mmol/l) is detected in about
20 % of hospitalised patients, whereas moderate-to-severe
hyponatraemia (serum Na+ < 130 mmol/l) occurs in about 7 %
of hospitalised patients [1, 2].
There is evidence that hyponatraemia is a clinical and social
problem because it is a frequent alteration especially in the
elderly and may strongly affect homeostasis of the brain as
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well as of different organs and tissues. Therefore, clinicians
should keep in mind the different aspects of hyponatraemia in
order to provide the best diagnostic procedures and treatment
strategies for their patients. This review covers the most im-
portant issues regarding hyponatraemia from aetiopatho-
genesis to diagnostic and therapeutic aspects. With regard to
treatment, a chapter has been dedicated to the newly available
therapeutic option represented by the vasopressin receptor
antagonists.
 Aetiopathogenesis
Hyponatraemia can be grossly divided into 2 main groups –
hypotonic and non-hypotonic forms. Non-hypotonic hypo-
natraemia is represented by hypertonic and isotonic hypo-
natraemia. The former occurs as a result of water shift from
cells into the extracellular fluid that is driven by solutes con-
fined in the extracellular compartment (eg, in hypergly-
caemia). It has been estimated that each glycaemia increase of
100 mg/dl above 100 mg/dl causes a serum Na+ reduction of
about 1.7 mmol/l [3]. Isotonic hyponatraemia may result from
the retention in the extracellular space of large volumes of iso-
tonic fluids that do not contain sodium (eg, absorption of
Abstract: Hyponatraemia is the most frequent
electrolyte disorder in hospitalised patients and
represents an important clinical and social prob-
lem. Hyponatraemia, particularly when acute
and severe, can be a life-threatening condition
and has been associated with an increased risk
of death. However, recent evidence shows that
also mild and chronic hyponatraemia can nega-
tively affect health status by causing for in-
stance gait disturbances, attention deficits, falls
and fracture occurrence as well as bone loss.
Many pathological conditions may be associated
with hyponatraemia. It may be divided into hyper-
tonic, isotonic, or hypotonic forms, based on os-
molality measurement. Attention should always
be dedicated to the assessment of fluid volume,
which is of pivotal importance in the diagnostic
work-up, together with laboratory data. A correct
diagnosis is mandatory in order to initiate appro-
priate treatment. Isotonic or hypertonic saline
solutions are used in hypovolaemic and normo-
volaemic/hypervolaemic hyponatraemia, respec-
tively. Fluid restriction is generally used in asymp-
tomatic normovolaemic/hypervolaemic hyponat-
raemia although its efficacy is rather poor. Vaso-
pressin receptor antagonists, also known as
vaptans, represent a new treatment option for
the correction of hyponatraemia. Vaptans pre-
vent free-water re-absorption and increase urine
volume by blocking the binding of vasopressin to
V2 receptors expressed in renal collecting duct
cells. Therefore, they should not be used in hypo-
volaemic hyponatraemia. Vaptans have been
shown to effectively correct serum sodium in
normovolaemic and hypervolaemic hyponatrae-
mia. While tolvaptan and conivaptan have been
approved in the US for the treatment of both
normovolaemic and hypervolaemic hyponatrae-
mia, in Europe only tolvaptan was approved in
2009 for the treatment of adult patients with hy-
ponatraemia secondary to the syndrome of inap-
propriate ADH secretion.
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Kurzfassung: Hyponatriämie ist die häufigste
Elektrolytstörung bei hospitalisierten Patienten
und stellt ein wichtiges klinisches und soziales
Problem dar. Sie kann vor allem in akuten und
schweren Fällen einen lebensbedrohenden Zu-
stand darstellen und wurde mit einem erhöhten
Mortalitätsrisiko in Verbindung gebracht. Rezen-
te Evidenz zeigt jedoch, dass auch milde und
chronische Hyponatriämie den Gesundheitssta-
tus negativ beeinflussen kann. Sie verursacht
z. B. Gangstörungen, Aufmerksamkeitsdefizite,
Stürze und damit verbunden Frakturen sowie
Knochenmasseverlust. Viele unterschiedliche Er-
krankungen sind mit Hyponatriämie assoziiert.
Sie kann, basierend auf der Osmolalitätsmes-
sung, in hypertone, isotone oder hypotone For-
men unterteilt werden. Aufmerksamkeit sollte
immer der Beurteilung des Flüssigkeitsvolumens
geschenkt werden, das zusammen mit den Labor-
ergebnissen von entscheidender Bedeutung für
das diagnostische Work-up ist. Eine korrekte
Diagnose ist Voraussetzung für eine passende
Behandlung. Isotone oder hypertone Salzlösun-
gen werden bei hypovolämischer bzw. normo-
volämischer/hypervolämischer Hyponatriämie
eingesetzt. Flüssigkeitsrestriktion wird generell
bei asymptomatischer normovolämischer/hyper-
volämischer Hyponatriämie eingesetzt, obwohl
ihre Wirksamkeit eher beschränkt ist. Vaso-
pressin-Rezeptorantagonisten, auch bekannt als
Vaptane, stellen eine neue Behandlungsoption
zur Korrektur der Hyponatriämie dar. Vaptane
verhindern die Reabsorption von freiem Wasser
und steigern das Urinvolumen durch Blockade
der Bindung von Vasopressin an V2-Rezeptoren,
die in renalen Sammelkanalzellen exprimiert
werden. Daher sollten sie im Fall einer hypo-
volämischen Hyponatriämie nicht eingesetzt
werden. Es konnte gezeigt werden, dass Vaptane
das Serum-Natrium bei normo- und hypervol-
ämischer Hyponatriämie effektiv korrigieren kön-
nen. Während in den USA Tolvaptan und Coni-
vaptan für die Behandlung sowohl der normo-
volämischen als auch der hypervolämischen Hypo-
natriämie zugelassen sind, wurde in Europa nur
Tolvaptan 2009 für die Behandlung erwachsener
Patienten mit Hyponatriämie sekundär zum Syn-
drom der ungünstigen ADH-Sekretion zugelas-
sen. J Klin Endokrinol Stoffw 2013; 6 (2): 17–
22.
Schlüsselwörter: Hyponatriämie, Syndrom der
ungünstigen antidiuretischen Hormonsekretion,
Syndrom der ungünstigen Antidiurese, Vasopres-
sin-Rezeptorantagonisten, Vaptane
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irrigants, glycine, sorbitol, or mannitol, contained in non-con-
ductive flushing solutions used in the post-transurethral resec-
tion of the prostate [TURP] or hysteroscopy). Furthermore,
the possibility to encounter a condition of pseudohyponatrae-
mia, which is the result of a laboratory artefact in the presence
of severe hypertriglyceridaemia or paraproteinaemia, has to
be remembered.
Hypotonic (dilutional) hyponatraemia is the consequence of
an excess of body water relative to total body sodium stores,
which can be normal, reduced, or increased [4]. It may result
from excessive water intake or renal water retention. Based on
extracellular fluid (ECF) volume, hypotonic hyponatraemia
can be classified clinically into 3 types: hypovolaemic, hyper-
volaemic, or normovolaemic [4] (Table 1).
Hypovolaemic hyponatraemia may be observed as a conse-
quence of renal solute loss (eg, diuretic therapy, cerebral salt
wasting syndrome, mineralocorticoid deficiency, salt wasting
nephropathy) or of extra-renal solute loss (eg, vomiting, diar-
rhoea, pancreatitis, third-space burns). Hypervolaemic hypo-
natraemia is classically associated with congestive heart fail-
ure, cirrhosis, nephrotic syndrome, and renal failure (acute or
chronic). Normovolaemic hyponatraemia is essentially repre-
sented by the syndrome of inappropriate secretion of antidi-
uretic hormone (SIADH) and accounts for about 60 % of all
causes of chronic hyponatraemia; “inappropriate” meaning
that it is not caused by plasma hyperosmolality or by arterial
hypotension or hypovolaemia. SIADH may be caused by
a number of different conditions, including for instance
tumours, central nervous system disorders, and pulmonary
diseases (Table 2). Ongoing drug treatment deserves particu-
lar attention because many drugs may affect water homeosta-
sis by inducing ADH release (eg, tricyclic antidepressants,
selective serotonin reuptake inhibitors, phenothiazines, car-
bamazepine, vinca alkaloids, alkylating agents, opiates) and/
or potentiating its effect (eg, carbamazepine, chlorpropamide,
alkylating agents, non-steroidal anti-inflammatory drugs).
This syndrome has been recently referred to as “syndrome of
inappropriate antidiuresis” (SIAD), following the first de-
scription of infants with clinical and laboratory features con-
sistent with the presence of SIADH, but with undetectable
ADH levels. In these patients, gain-of-function mutations in
the vasopressin-type 2 (V2) receptor gene were identified [5].
Despite the fact that the syndrome has so far not been formally
renamed, the new term SIAD should be preferred in the opin-
ion of the author because it includes this type of patients as
well.
In patients with SIAD impaired renal water excretion occurs
and causes a slight increase in total body water. However, pa-
tients do not develop oedema because signs of water excess
are prevented by distribution of water in both intra- and extra-
cellular compartments of the body [4] and by sodium urinary
excretion promoted mainly by the increased secretion of
natriuretic peptides [6]. Normovolaemic hyponatraemia may
be also associated with secondary hypocortisolism, in which
the clinical and biochemical features are barely distinguish-
able from those of SIAD [7, 8]. In secondary hypocortisolism,
the main cause of hyponatraemia seems to be an increased
production of ADH, which depends mainly on loss of the
tonic inhibitory effect on ADH secretion by endogenous cor-
tisol [9]. Nevertheless, other factors can also exert a similar
effect, such as nausea and hypoglycaemia [8]. Furthermore,
there is evidence that hypocortisolism causes up-regulation of
Table 1. Main features of hypotonic hypervolaemic, normovolaemic, or hypovolaemic hyponatraemia.
Hypervolaemic Normovolaemic Hypovolaemic
hyponatraemia hyponatraemia hyponatraemia
Total body water   
Total body sodium   
Extracellular fluid volume   / 
Oedema Present Absent Absent
Cause Congestive heart failure, SIAD, hypocortisolism, Renal solute loss: diuretic therapy,
cirrhosis, nephrotic syndrome, hypothyroidism cerebral salt wasting syndrome,
acute or chronic renal failure Addison’s disease, salt wasting
nephropathy
Extrarenal solute loss: vomiting,
diarrhoea, pancreatitis, third-space
burns
Table 2. Causes of the syndrome of inappropriate diuresis.
Tumours
Pulmonary/mediastinal
Non-chest (eg, duodenal carcinoma, pancreatic carcinoma, ure-
thral/prostate carcinoma, leukaemia, nasopharyngeal carcinoma)
Central nervous system disorders
Mass lesions (tumours, brain abscesses, subdural haematoma)
Inflammatory diseases (eg, encephalitis, meningitis, multiple scle-
rosis)
Degenerative/demyelinating diseases
Miscellaneous (eg, subarachnoid haemorrhage, head trauma,
pituitary stalk section, hydrocephalus)
Drug-induced
Stimulated vasopressin release
Direct renal effects and/or potentiation of vasopressin antidiuretic
effects
Mixed or uncertain actions
Pulmonary diseases
Infections (eg, tuberculosis, acute bacterial and viral pneumonia)
Mechanical/ventilatory (eg, acute respiratory failure, positive pres-
sure ventilation)
Other
AIDS
Prolonged strenuous exercise (eg, marathon, hot-weather hiking)
Idiopathic
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aquaporin-2 water channels, thus reducing renal free water
excretion [10]. Finally, a possible cause of normovolaemic
hyponatraemia is hypothyroidism. Here, decreased cardiac
output and effective arterial blood volume negatively affect
glomerular filtration rate, thus determining increased proxi-
mal tubular water re-absorption and increased ADH secretion
[11]. However, a study reported that the distribution of serum
Na+ in patients with or without hypothyroidism was virtually
the same [12]. This is in agreement with the calculated 0.14-
mmol/l reduction of serum Na+ for each 10-mU/l increase of
TSH.
 Clinical Features
Symptoms of hyponatraemia relate mostly to central nervous
system dysfunction and are the consequence of water entry
into nerve cells due to the hypotonic state [2, 4]. Symptoms
depend on serum Na+ and, particularly, on the rate of its de-
cline. Therefore, the degree of symptomatology exhibited by
patients with hyponatraemia may be used as a surrogate for
the duration of this electrolyte alteration, which may be un-
known. Stupor, coma, convulsions, and respiratory arrest may
be present in life-threatening, usually acute hyponatraemia,
whereas headache, irritability, nausea/vomiting, mental slow-
ing, confusion, and disorientation are more likely associated
with symptomatic chronic hyponatraemia. For instance, a
single-hospital study reported that stupor or coma occurred in
only 6 % of patients with chronic hyponatraemia compared to
100 % with those presenting acute hyponatraemia [13].
Mild, chronic hyponatraemia has traditionally been consid-
ered as an asymptomatic or mildly symptomatic condition.
However, there is increasing evidence that also mild and
chronic serum Na+ reduction may negatively affect health sta-
tus. It has been demonstrated, for instance, that apparently
asymptomatic hyponatraemia is associated with falls, un-
steadiness, attention deficits [14], and fracture occurrence
[15, 16]. Furthermore, there is evidence suggesting that sus-
tained hyponatraemia is associated with bone loss. This has
been demonstrated in a rat model of SIAD, in which the
analysis of bone architecture of excised femurs from normo-
and hyponatraemic animals showed reduced bone mass in the
latter group [17]. Accordingly, data from the Third National
Health and Nutrition Examination Survey (NHANES III)
showed that hyponatraemia remained a significant predictor
of osteoporosis following adjustment for age, sex, Body Mass
Index, physical activity, serum vitamin D, and diuretic use
[17]. Furthermore, chronic hyponatraemia has been shown to
exacerbate multiple manifestations of senescence in aged rats,
including senile osteoporosis, sarcopenia, cardiac fibrosis,
and hypogonadism [18]. The association between hypo-
natraemia and in-hospital mortality has been demonstrated in
numerous studies. Noticeably, a large cohort study, which in-
cluded all adult hospitalizations (n = 53,236) at an academic
medical centre between 2000 and 2007, demonstrated that
even mild hyponatraemia was associated with increased in-
hospital mortality and that the risk of death was increased by
2.3 % for each 1-mmol/l decline of serum Na+ [19].
 Diagnosis
For a correct diagnostic approach several issues have to be
considered: a patient’s clinical history, medications, and co-
morbidities have to be taken into account. Time should be
dedicated to the clinical examination of patients and, in par-
ticular, signs of volume depletion or excess should be looked
for. This information will then be complemented by labora-
tory data: serum and urine electrolytes, glycaemia, urea, crea-
tinine, uric acid, serum and urine osmolality, haematocrit, lip-
ids, proteins, serum cortisol, TSH, and fT4 should be mea-
sured. These data should provide enough information to es-
tablish a correct diagnosis. In particular, ECF assessment,
serum, and urine osmolality are of pivotal importance in the
diagnostic work-up (Figure 1). With regard to SIAD, the es-
Figure 1. Suggested flow-chart for the differential diagnosis of
hyponatraemia.
ECF: extracellular fluid; SIAD: syndrome of inappropriate
antidiuresis.
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sential diagnostic criteria are reported in Table 3. One of the
most challenging situations is represented by the differential
diagnosis between SIAD and cerebral salt wasting (CSW)
syndrome: the latter condition usually arises within a few
days after a neurosurgical procedure, stroke, or subarachnoid
haemorrhage. Some of the features of CSW are virtually iden-
tical to those of SIAD. In both conditions, hypotonic hypo-
natraemia, inappropriate urinary osmolality, and inappropri-
ately high urinary sodium excretion occur. However, a funda-
mental difference is represented by the fact that while SIAD
is classically considered a normovolaemic hyponatraemia,
CSW is a hypovolaemic condition. Therefore, the presence of
clinical signs of dehydration and biochemical signs of haemo-
concentration will suggest the diagnosis of CSW.
 “Traditional” Treatment
When approaching the treatment of hyponatraemia, physi-
cians should try to cure the underlying disorder and this step
may itself correct the electrolyte disorder: thiazide diuretics
and drugs inducing SIAD should be discontinued, if possible,
and hormone replacement therapy should be started in pa-
tients with hypocortisolism or hypothyroidism.
The assessment of ECF is of crucial importance in the evalua-
tion of the correct treatment of hypotonic hyponatraemia. If
hypovolaemia is present, isotonic saline (0.9 % NaCl) infu-
sion should be initiated. Sometimes, it may be difficult to as-
certain whether a patient is normovolaemic or slightly hypo-
volaemic. In this case, it is considered appropriate to start with
isotonic saline solution. This approach may also be consid-
ered as a diagnostic challenge because if euvolaemic, rather
than hypovolaemic, hyponatraemia is present, no improve-
ment of serum Na+ will be achieved [6].
In case of symptomatic euvolaemic or hypervolaemic hypo-
natraemia, infusion of hypertonic saline (3 % NaCl) repre-
sents the mainstay of treatment. Hypertonic saline is usually
associated with furosemide (especially in hypervolaemic con-
ditions), which induces diuresis equivalent to giving a one-
half isotonic saline solution, thus favouring the correction of
hyponatraemia [4]. The rate of correction of hyponatraemia
represents a crucial point and the risk of overly rapid correc-
tion or of overcorrection should never be underestimated.
Overly aggressive therapy with hypertonic saline raises serum
Na+ to the point that extracellular fluid is more concentrated
than intracellular fluid, drawing more water out of the brain
cells and possibly causing the syndrome of osmotic demyeli-
nation. Most reported cases of this dramatic event occurred
after rates of correction > 12 mmol/l/day, but some cases oc-
curred also after corrections of 9 mmol/l/day. It has to be
said that in most of these cases other associated risk factors
for cerebral demyelination were present, such as malnutri-
tion, hypokalaemia, or liver disease [20]. Nonetheless, it is
recommended not to exceed a correction of 8 mmol/l/day.
A higher initial rate of correction (2–3 mmol/l/h) is indicated
only in cases of acute (< 48 h) and severe hyponatraemia
(Na+ < 115 mmol/l) because of the high risk of severe morbid-
ity and death. As a general rule, hypertonic saline infusion
should be stopped when the patient becomes asymptomatic
and/or serum Na+ reaches 125 mmol/l. The formula proposed
by Adrogué and Madias can be used to calculate the rate of
saline infusion [4].
In patients with asymptomatic hyper- or euvolaemic hypo-
natraemia, fluid restriction represents the safe mainstay of
management [4]. In SIAD, fluid restriction can be associated
with a high-sodium diet (10 g/day orally). However, fluid re-
striction usually corrects hyponatraemia by only 1–2 mmol/
l/day, even when severe (< 500 ml/day) [21]. Furthermore,
fluid restriction is poorly tolerated because of increased
thirst with subsequent poor compliance. Finally, fluid re-
striction requires the patient to excrete free water. Free water
clearance by the kidney can be predicted using the urine/se-
rum (U/S) electrolyte ratio [22]. If the U/S ratio is ≥ 1, free-
water clearance is negative and no excretion of free water is
expected.
Other options for the treatment of eu- or hypervolaemic
hyponatraemia, such as demeclocycline, urea, or lithium, are
considered suboptimal for several reasons, including variable
efficacy, slow responses, and toxic effects [23, 24].
 The New Frontier: Vasopressin Receptor
Antagonists
A new aera for the treatment of hyponatraemia was started
with the development of non-peptide vasopressin receptor
antagonists, the so-called vaptans. In particular, vaptans block
ADH binding to V2 receptors expressed in renal collecting
duct cells. This inhibits the synthesis and transport of
aquaporin-2 water channel proteins into the apical membrane
of these cells, thus preventing free-water re-absorption and
causing increased urine volume [25]. Therefore, vaptans
cause water diuresis, namely aquaresis, thus increasing serum
Na+. In 1993, the first successful use of a non-peptide V2 re-
ceptor antagonist was reported in humans [26].
Several vaptans have been developed and tested in humans,
including tolvaptan, conivaptan, lixivaptan, mozavaptan,
satavaptan, and RWJ351647 [27]. Because of their mecha-
nism of action, vaptans are not to be used in hypovolaemic
hyponatraemia. Currently, only one selective V2 receptor an-
tagonist, tolvaptan, is available on the market in Europe and
in the US. In Europe, tolvaptan (oral tablet) was approved by
Table 3. Essential diagnostic criteria of SIAD.
Hyponatraemia (serum Na+ < 136 mmol/l)
Plasma hypo-osmolality (< 275 mOsm/kg)
Urine osmolality > 100 mOsm/kg
Clinical normovolaemia
No clinical signs of hypovolaemia (orthostatic decreases in
blood pressure, tachycardia, decreased skin turgor, dry mucous
membranes)
No clinical signs of hypervolaemia (oedema, ascites)
Increased urinary sodium excretion (> 40 mmol/l with normal
salt and water intake)
Absence of other potential causes of euvolaemic hypo-osmolality:
exclude recent diuretic use, renal disease, hypocortisolism, and
hypothyroidism
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the European Medicines Agency (EMA) on August 9, 2009,
with the indication “treatment of adult patients with hypo-
natraemia secondary to SIADH”. In the US, tolvaptan was
approved by the Food and Drug Administration (FDA) on
May 29, 2009, for the “treatment of clinically significant
hypervolaemic and euvolaemic hyponatraemia”, thus includ-
ing patients with heart failure and cirrhosis. Another vaptan
with partial affinity also for the V1 receptor, conivaptan (injec-
tion formulation), was approved on December 29, 2005, in
the US for the “treatment of euvolaemic and hypervolaemic
hyponatraemia in hospitalised patients”.
Because this review addresses endocrinologists and because
only tolvaptan is available at this time as an oral formulation
for the treatment of hyponatraemia secondary to SIAD, the
main trials regarding this drug, which included patients with
SIAD, and the lessons we have learned on clinical grounds in
the last couple of years will be summarised here.
The efficacy of tolvaptan in patients with eu- or hypervolae-
mic hyponatraemia was evaluated in 2 multicentre, random-
ized, double-blind, placebo-controlled trials, the Study of As-
cending Levels of Sodium in hyponaTraemia 1 and 2 (SALT-
1 and SALT-2) [28]. Serum Na+ increased to a greater extent
in the tolvaptan group (n = 225, 15–60 mg/day) than in the
placebo group (n = 223) during the first 4 days and at comple-
tion of the treatment period (30 days). At baseline, this differ-
ence was present both in patients with mild (130–135 mmol/l)
or moderate/severe (< 130 mmol/l) hyponatraemia. Increased
thirst and dry mouth were the most commonly observed side
effects in agreement with the aquaretic effect of the drug. An
overly rapid correction of hyponatraemia or overcorrection
occurred in < 2 % of patients. Interestingly, a combined analy-
sis of SALT-1 and SALT-2 revealed that patients treated with
tolvaptan reported a significant increase in the score of the
mental component of the SF-12 health survey from baseline
to day 30. A subsequent subgroup analysis of patients with
SIAD (n = 110) in SALT-1 and SALT-2 confirmed a greater
increase in serum Na+ in patients in the tolvaptan group com-
pared to the placebo group [29]. In SIAD patients, the SF-12
Health Survey revealed a significantly positive effect of
tolvaptan on the physical component, but a near-significant
trend was also observed on the mental component.
Figure 2. Indications for the use of tolvap-
tan.
* according to the European indication, which
restricts the use of tolvaptan only in pa-
tients with hyponatraemia secondary to SIAD.
The long-term use of tolvaptan was assessed in another subse-
quent trial, SALTWATER, a multicentre, open-label exten-
sion of SALT-1 and SALT-2 [30]. In this trial, hyponatraemic
patients (n = 111) were treated with tolvaptan for a mean fol-
low-up of almost 2 years. Prompt normalisation of serum Na+
was reported and normal values were maintained throughout
the observation period. The safety of tolvaptan was also con-
firmed in this trial and an excessive rate of correction or
hypernatraemia was rarely observed.
In European clinical practice, the use of tolvaptan may be
considered a valuable option in patients with hyponatraemia
due to SIAD who have moderate symptoms (eg, confusion,
disorientation, nausea, unsteady gait) as an alternative to hy-
pertonic saline infusion. In addition, tolvaptan may be effec-
tively used in SIAD patients with mild symptoms related to
hyponatraemia (eg, mild neurocognitive alterations, depres-
sion) or in asymptomatic patients, if fluid restriction fails or
is not tolerated [31, 32] (Figure 2). In some instances,
tolvaptan may also be considered as the first-choice treat-
ment to correct hyponatraemia. This can be the case in surgi-
cal or neoplastic patients in order to achieve rapid correction
and avoid treatment delay. Tolvaptan may be also used as the
first-choice option in hyponatraemic patients with SIAD,
when the kidneys are not expected to excrete solute-free
water (U/S electrolyte ratio ≥ 1) or as a trial to treat symp-
toms likely caused by hyponatraemia. On the other hand, it
has to be kept in mind that in patients with severely symp-
tomatic hyponatraemia (eg, respiratory distress, seizures,
coma) active treatment with hypertonic saline remains the
recommended treatment option.
When using vaptans, the general rules regarding the rate
of correction of serum Na+ should be applied and frequent
electrolyte monitoring is required. There is evidence, for in-
stance, that in patients with very low serum Na+ at baseline
(≤ 120 mmol/l) greater responses may occur [33] and, re-
cently, both the EMA and FDA have reinforced recommenda-
tions about fluid and electrolyte monitoring in patients treated
with vaptans. In case of an excessive increase in serum Na+,
administration of the drug should be stopped or the dose
should be reduced; furthermore, the use of hypotonic fluid
should be considered [23].
22 J KLIN ENDOKRINOL STOFFW 2013; 6 (2)
Hyponatraemia
 Conclusions and Practical Relevance
Hyponatraemia is a biochemical sign that can be associated
with a number of different pathological conditions. Hypo-
natraemia per se represents a problem of clinical and social
relevance and a correct diagnostic work-up should be per-
formed in order to provide the most appropriate treatment
to patients. Although extensive comparative research of
vaptans vs other therapies and analyses of patients treated
with these drugs are needed to better define their real effec-
tiveness in clinical practice, vaptans appear to be an addi-
tional useful and safe tool, if appropriately used, for the
correction of hyponatraemia.
 Relevanz für die Praxis
Hyponatriämie ist ein biochemischer Zustand, der mit einer
Vielzahl verschiedener pathologischer Zustandsbilder in
Verbindung gebracht wird. Die Hyponatriämie per se ist
ein Problem von klinischer und sozialer Relevanz und ein
korrektes diagnostisches Work-up sollte durchgeführt wer-
den, um den Patienten die beste passende Behandlung bie-
ten zu können. Obwohl die ausführliche vergleichende
Forschung an Vaptanen im Vergleich zu anderen Therapie-
formen sowie Analysen der mit diesen Substanzen behan-
delten Patienten notwendig ist, um deren wirkliche Effekti-
vität in der klinischen Praxis definieren zu können, schei-
nen Vaptane bei korrekter Anwendung ein zusätzliches,
sinnvolles und sicheres Mittel zur Korrektur einer Hypona-
triämie zu sein.
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